The U.S. Inhalation Anesthesia Market was valued at USD 743.8 million in 2024, and is projected to reach USD 1.06 billion by 2030, rising at a CAGR of 6.10%. The market's growth is attributed to the rising demand for shorter hospital stays and increasing surgical procedures. Inhalation anesthesia offers higher patient outcomes compared to intravenous anesthesia, as administering anesthetic agents through the respiratory tract allows for more controllable, effective sedation that is both cost-effective and safe.
Inhalation anesthesia creates a reversible state of unconsciousness and loss of sensation, making it essential for pain-free surgeries. It is widely used for general anesthesia in various surgical settings, especially in outpatient, pediatric, and needle-phobic patients. Inhalation anesthetics are also valuable in diagnostic procedures and can be utilized outside the operating room for ICU sedation or conditions such as status asthmaticus. In addition, agents such as nitrous oxide provide moderate sedation in dental settings.
According to the National Library of Medicine, around 40 to 50 million major surgeries are conducted annually in the U.S. Inhalation anesthesia is critical for cancer diagnoses and biopsies, offering comfort during these procedures. The National Cancer Institute estimates that in 2024, about 2,001,140 new cancer cases will be diagnosed in the U.S., including 14,910 cases in children and adolescents. This rising cancer incidence is expected to boost the demand for inhalation anesthesia, particularly in pediatric and adult oncology care.
This product will be delivered within 2 business days.
Inhalation anesthesia creates a reversible state of unconsciousness and loss of sensation, making it essential for pain-free surgeries. It is widely used for general anesthesia in various surgical settings, especially in outpatient, pediatric, and needle-phobic patients. Inhalation anesthetics are also valuable in diagnostic procedures and can be utilized outside the operating room for ICU sedation or conditions such as status asthmaticus. In addition, agents such as nitrous oxide provide moderate sedation in dental settings.
According to the National Library of Medicine, around 40 to 50 million major surgeries are conducted annually in the U.S. Inhalation anesthesia is critical for cancer diagnoses and biopsies, offering comfort during these procedures. The National Cancer Institute estimates that in 2024, about 2,001,140 new cancer cases will be diagnosed in the U.S., including 14,910 cases in children and adolescents. This rising cancer incidence is expected to boost the demand for inhalation anesthesia, particularly in pediatric and adult oncology care.
U.S. Inhalation Anesthesia Market Report Highlights
- Based on drug, the sevoflurane drug dominated the U.S. inhalation anesthesia industry, accounting for the largest revenue share of 75.5% in 2024. The demand is driven by its popularity in day surgery due to the quick attainment of deep anesthesia and faster recovery times.
- The isoflurane drug segment is expected to grow significantly over the forecast period.
- Based on application, the maintenance phase dominated the market with the largest revenue share in 2024. However, the induction phase is expected to grow at a significant CAGR over the forecast period.
- Based on end use, the hospitals segment led the U.S. inhalation anesthesia industry with the largest revenue share in 2024.
- The Ambulatory Surgical Centers (ASC) end use segment is expected to grow at the fastest CAGR of 7.0% over the forecast period.
- The growing number of surgical procedures, including orthopedics, ophthalmology, gastroenterology, ENT, cosmetic surgeries, urology, gynecology, and podiatry, in ASCs is expected to drive the demand for inhalation anesthesia in the coming years.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Inhalation Anesthesia Market Variables, Trends, & Scope
Chapter 4. U.S. Inhalation Anesthesia Market: Service Business Analysis
Chapter 5. U.S. Inhalation Anesthesia Market: Formulation Business Analysis
Chapter 6. U.S. Inhalation Anesthesia Market: End Use Business Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this U.S. Inhalation Anesthesia market report include:- Baxter
- AbbVie Inc.
- Piramal Enterprises Ltd.
- Hikma Pharmaceuticals PLC
- Halocarbon, LLC
- Sandoz Group AG
- Fresenius Kabi AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 743.8 Million |
| Forecasted Market Value ( USD | $ 1060 Million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 8 |
